US 9,808,526 B2
Pharmaceutical kit and methods for cancer treatment via intracavity delivery and for preparing metal nanoparticle-antibody fragment conjugate
Chieh Hsiao Chen, Taichung (TW)
Filed by Chieh Hsiao Chen, Taichung (TW)
Filed on Jul. 12, 2016, as Appl. No. 15/208,553.
Application 15/208,553 is a division of application No. 14/132,937, filed on Dec. 18, 2013, granted, now 9,415,238.
Prior Publication US 2016/0317659 A1, Nov. 3, 2016
Int. Cl. A61K 41/00 (2006.01); A61K 39/00 (2006.01); A61N 5/06 (2006.01); A61K 47/48 (2006.01); A61K 49/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61N 5/067 (2006.01)
CPC A61K 41/0052 (2013.01) [A61K 47/48607 (2013.01); A61K 47/48861 (2013.01); A61K 49/0008 (2013.01); A61N 5/062 (2013.01); C07K 16/2863 (2013.01); C07K 16/3092 (2013.01); A61K 2039/505 (2013.01); A61N 2005/067 (2013.01); A61N 2005/0662 (2013.01); A61N 2005/0663 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A method for cancer treatment via intracavity delivery, comprising the steps of:
a) preparing a metal nanoparticle-antibody fragment conjugate, wherein the metal nanoparticle is modified with carboxyl group or polyethylene glycol (PEG) and covalently bound to the antibody fragment comprising sulfhydryl group, wherein said antibody fragment is one of a half-antibody fragment and a monoclonal antibody fragment;
b) administering the conjugate to a cancer cell; and;
c) providing a spherical or superficial green laser light source to irradiate the metal nanoparticle-antibody fragment conjugate bonded to the cancer cell.